Navigation Links
Myriad Genetics Presents Azixa's Mode of Action at AACR

Azixa Shows Dual Activity as Vascular Disrupting Agent and Tubulin Inhibitor

SALT LAKE CITY, UT, April 17, 2007—Myriad Genetics, Inc. (NASDAQ: MYGN) (www.myriad.com) announced today that it presented studies that characterize the mode of action of its investigational new drug, Azixa™, as a vascular disrupting agent, at the annual meeting of the American Association for Cancer Research (AACR) in Los Angeles, California.

Azixa has been previously shown to be an inducer of apoptosis, and a potent inhibitor of human tumor cell growth and survival in cell culture, regardless of the multiple drug resistance (MDR) stature of the tumors. Key to this activity is its ability to inhibit the formation of microtubules. Data on Azixa's activity against human cancers of the breast, ovary, prostate, colon and pancreas will be presented at ASCO, the American Society of Clinical Oncology, later this year. Recently, Myriad researchers have uncovered a second mode of action known as vascular disruption.

Vascular disrupting agents target a tumor's endothelium, the inner layer of cells lining a blood vessel, which leads to a loss of blood supply to the tumor and subsequent tumor cell death. In recent studies, Azixa induced cell death in several primary types of endothelium, including micro-vessel endothelial cells. Moreover, in human ovarian cancer xenografts, a single dose of Azixa induced dramatic tumor blood vessel damage and tumor cell death within 24 hours.

"We are excited by the potential of Azixa in several different types of cancer," said Adrian Hobden, Ph.D., President of Myriad Pharmaceuticals, Inc. "Azixa's dual mode of action and its extraordinary ability to cross the blood-brain barrier may allow it to be a more effective chemotherapeutic than anything available to treat brain cancer today."

Azixa's dual mode of action i s essential to its ability to inhibit tumor growth. It is believed that Azixa selectively disrupts tumor vasculature by inhibiting the formation of microtubules. Tumors rely on microtubules to maintain the cytoskeletal structure of their new vasculature, whereas mature vascular endothelium of healthy tissue uses actin filaments to provide the needed structure. Therefore, tumor vasculature is selectively targeted, leaving healthy normal tissue unaffected.

Azixa is currently being evaluated in two Phase 2 human clinical trials, one in patients with primary brain cancer and the other in melanoma that has spread to the brain.

Azixa is a trademark of Myriad Genetics, Inc. in the U.S. and other countries.

Myriad Genetics, Inc. is a biopharmaceutical company focused on the development of novel healthcare products. The Company develops and markets predictive medicine products, and is developing and intends to market therapeutic products. Myriad's news and other information are available on the Company's Web site at www.myriad.com.

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements relating the potential for Azixa to treat cancer of several different types. These risks and uncertainties include, but are not limited to, our inability to further identify, develop and achieve commercial success for new products and technologies; our ability to discover drugs that are safer and more efficacious than our competitors; our ability to develop molecular diagnostic products that help assess which patients are subject to greater risk of developing diseases and who would therefore benefit from new preventive therapies; the possibility of delays in the research and development necessary to select drug development candidates and delays in clinical trials; the risk that clinica l trials may not result in marketable products; the risk that we may be unable to successfully finance and secure regulatory approval of and market our drug candidates, or that clinical trials will be completed on the timelines we have estimated; uncertainties about our ability to obtain new corporate collaborations and acquire new technologies on satisfactory terms, if at all; the development of competing products and services; our ability to protect our proprietary technologies; patent-infringement claims; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading "Risk Factors" contained in Item 1A in our Annual Report on Form 10-K for the year ended June 30, 2006, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.


'"/>




Related medicine technology :

1. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
2. Myriad Genetics Presents Tumor Origin Technology at AACR
3. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
4. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
5. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
6. ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
7. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
8. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
9. Expression Genetics, Inc. Announces Successful Completion of Phase I Trial of Gene-Based IL-12 for Treatment of Ovarian Cancer
10. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
11. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... 8, 2016   HighPoint Solutions today ... (NRG),s pharmacovigilance technology services division.  NRG is a ... an Oracle Argus Specialized partner, providing drug safety ... companies. --> --> ... sciences capabilities and provides a global scale and ...
(Date:2/8/2016)... BOSTON , Feb. 8, 2016   Intarcia ... John Yee , MD, MPH, into the newly created ... Safety and Operations. Dr. Yee has two decades of ... companies, and at a major academic medical center. Most ... Affairs, US Diabetes, and VP, US Head Medical Officer ...
(Date:2/8/2016)... Calif. , Feb. 8, 2016 Lonza, a ... Sciences Inc., a biopharmaceutical company designing and developing novel ... agreements for the clinical supply of Kodiak,s therapeutic candidates. ... sites, including Slough (UK), Visp (CH) and Nansha (CN). ... Retinal diseases, such as age-related macular degeneration (AMD), cause ...
Breaking Medicine Technology:
(Date:2/9/2016)... ... 09, 2016 , ... Sir Grout, the leading hard surface ... announce that many of their franchises have received the Super Service Award from ... franchises received customer recognition through positive reviews and testimonials, as well as evaluations ...
(Date:2/8/2016)... ... February 08, 2016 , ... CURE Media Group , the nation’s leading ... Multiple Myeloma Heroes Awards event , which will annually honor individuals making heroic contributions ... MM. The MM Heroes Awards nomination process is officially open through February ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... LA, celebrates the beginning of a new charity campaign. As part of their ... Special Advocates (CASA). In the belief that children deserve a voice, and in ...
(Date:2/8/2016)... ... February 08, 2016 , ... If you are feeling that your clothes ... not alone. According to the Center for Disease Control and Prevention (CDC), 34.9% of ... and certain types of cancer, some of the leading causes of preventable death. ...
(Date:2/8/2016)... ... February 08, 2016 , ... Local insurance ... greater Venice, FL area, has initiated a fundraiser for a two year old ... four days after Christmas. To support this beautiful child who is facing life’s ...
Breaking Medicine News(10 mins):